Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Phase III, Multicentre, 52-week Study, Evaluating the Safety and Efficacy of Symbicort® Turbuhaler® (1, 2, and 4 x 160/4.5 µg Twice Daily) in Japanese Patients With Asthma

NCT00255255 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00255255
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00255255 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Phase III, Multicentre, 52-week Study, Evaluating the Safety and Efficacy of Symbicort® Turbuhaler® (1, 2, and 4 x 160/4.5 µg Twice Daily) in Japanese Patients With Asthma
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2005
Completion date
June 30, 2007
Enrollment
120
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

asthma